anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Immune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a promising therapeutic avenue for managing ITP by interfering with BAFF activity and long-lived plasma cell production. Both clinical and experimental studies have yielded positive outcomes when combining rituximab with an anti-BAFF monoclonal antibody in treating ITP. In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral BAFF-R+ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP.
The invention discloses a plaster for treating rheumatic rheumatoid arthritis, and a preparation method thereof. The plaster provided by the invention comprises forty traditional Chinese medicine components including radix clematidis, rhizoma homalomenae, schizophragma integrifolium, common clubmoss herb, spatholobi caulis, ephedra herb, argy wormwood leaves, garter snake, radix angelicae dahuricae, notopterygium root, pubescent angelica root, angelica sinensis, etc. The plaster provided by the invention is convenient for preparation and use, is safe for clinic applications, can reach disease sites directly, has many absorption of effective components and good effectiveness of the medicines, has a significant curative effect, treats both the symptoms and root causes, and does not stimulate viscera. By compatibility of the medicines, a curative effect is increased; drug property is changed or alleviated; and toxicity and side effects of the medicines are reduced or eliminated. The traditional Chinese medicine plaster provided by the invention is specialized for treating the rheumatic rheumatoid arthritis, and has relatively good effects for curing and alleviating symptoms of the rheumatic rheumatoid arthritis. 218 cases are treated and a total efficiency reaches 97%. Besides, the plaster provided by the invention contains camphor and plum borneol, and can increase transdermal capability of corticosteroids by 8-10 times.
FIELD: medicine, microbiology. SUBSTANCE: method deals with preparing immune sera. The method deals with applying microbes of B.mallei C-5 strain as an industrial one with the help of which, after adding phenol and heating, one should prepare a corpuscular antigen to be used for intravenous cyclic immunization of rabbits according to a certain scheme. Sera are obtained on the 10th d after immunization and lyophilized. The method provides to obtain a highly active and stable polyvalent glanderous serum useful to control the quality of erythrocytic antigenic glanderous diagnostic kit and agglutinogenic properties of glanderous agent's cultures. EFFECT: higher efficiency. 4 tbl
Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
Antibiotic producing micro-organisms are cultured in a nutrient medium to which is added insulin or desoxycorticosterone as such, or in the form of an ester, e.g. propionate and acetate, or a glycoside, e.g. glucoside, said addition being at any time between the preparation of the nutrient and 24 hours after the nutrient medium has been inoculated, preferably under sterilizing conditions.  The nutrient may be any medium (see Group VI), temperature 5 DEG  to 41 DEG  C., preferably 36 DEG  to 37 DEG  C.  The maximum addition of hormone per litre nutrient is 10 international units of insulin or 10 m.g. desoxycorticosterone; this may be reduced to 1/10 , \ba1/100 or even 1/1000 .  A mixture of insulin and desoxycorticosterone may be used.  Specified micro-organisms are Penicillium notatum, Streptomyces griseus and Streptomyces venezuala.  Aureomycin, terramycin and neomycin - producing microorganisms may be used.ALSO:A process of the culture of micro-organisms including viruses, comprises adding to a nutrient medium insulin or desoxycorticosterone, as such, or in the form of an ester e.g. propionate and acetate or glycoside e.g. glucoside, said addition being at any time between the preparation of the nutrient and 24 hours after the nutrient medium has been inoculated, preferably under sterilising conditions.  The nutrient medium is beef broth agar, sheep or horse blood agar, Capeck-Dox solution, or any suitable nutrient e.g. sodium chloride, urea, mannitol, glycogen in aqueous solution.  The temperature of cultivation is 5 to 41 DEG  C., preferably 36 to 37 DEG  C.  The maximum addition of hormone per litre of nutrient is 10 international units of insulin or 10 mg. desoxycorticosterone; this may be reduced to 1/10, 1/100 or even 1/1000.  Sterilisation may be by heating to 100-120 DEG  C., by filtering through a bacteria proof filter or by factional sterilisation at 80 or 100 DEG  C.  A mixture of insulin and desoxycorticosterone may be used.  Micro-organisms which may be so cultivated are Bacterium coli, B. hemophilus, Staphyloccus aureus, streptococci and antibiotic-producing micro-organisms (see Group IV (b)).
Patients with end stage renal disease may develop hypercalcemia when treated with calcium, including calcium acetate (ELIPHOS®). Avoid the use of calcium supplements, including calcium-based nonprescription antacids, concurrently with ELIPHOS®.

An overdose of ELIPHOS® may lead to progressive hypercalcemia, which may require emergency measures. Therefore, early in the treatment phase during the dosage adjustment period, monitor serum calcium levels twice weekly. Should hypercalcemia develop, reduce the ELIPHOS® dosage, or discontinue the treatment, depending on the severity of hypercalcemia.

More severe hypercalcemia (Ca >12 mg/dL) is associated with confusion, delirium, stupor and coma. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing ELIPHOS® therapy.

Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting. Mild hypercalcemia is usually controlled by reducing the ELIPHOS® dose or temporarily discontinuing therapy. Decreasing or discontinuing Vitamin D therapy is recommended as well.

Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification. Radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification. The long term effect of ELIPHOS® on the progression of vascular or soft tissue calcification has not been determined.

Hypercalcemia (>11 mg/dL) was reported in 16% of patients in a 3-month study of solid dose formulation of calcium acetate; all cases resolved upon lowering the dose or discontinuing treatment.

Maintain the serum calcium-phosphorus (Ca × P) product below 55 mg2/dL2.
The invention provides a traditional Chinese medicine composition for treating cerebral infarction. Cerebral infarction belongs to the field of 'stroke' in traditional Chinese medicine and is complicated in pathogenesis. Many doctors consider that the basic pathogenesis of cerebral infarction is 'asthenia in origin and asthenia in superficiality' and point out that the symptoms of cerebral infarction are mainly 'phlegm, fire, wind and stasis' in the initial stage and 'asthenia and stasis' in the later stage. Treatment of the cerebral infarction shall obey the rules of clearing away heat, relieving dizziness, tonifying qi, dredging collaterals, promoting blood circulation and removing stasis. Therefore, peach kernel, safflower, chrysanthemum, concha haliotidis, lotus leaves, radix bupleuri, radix bupleuri, semen coicis, roasted rhizoma atractylodis macrocephalae, ligusticum wallichii, uncaria rhynchophylla, selfheal, arisaema cum bile, red paeony root, lumbricus, rhizoma acori graminei and radix salviae miltiorrhizae are selected and prepared into a decoction which is taken by patients. Through clinical observation, the total effective rate of the traditional Chinese medicine composition reaches 100%; the traditional Chinese medicine composition is safe and effective, low in cost, convenient to control and worth of clinical popularization and application.
This is a prospective longitudinal study of adult patients with chronic obstructive pulmonary disease (COPD) who will be enrolled when their COPD is considered clinically stable or during an acute exacerbation. This design will allow both within-person and between-person comparisons by exacerbation experience. Comprehensive clinical and patient-reported assessments will be performed at baseline and at 3 months (end of study). Subsets of items will be administered by interactive voice response (IVR) over the course of the study to measure changes in key symptoms over the course of recovery from an exacerbation. A subset of patients will be interviewed at the end of the study to assess content validity of PROMIS items in this patient population.

With such a study design, we will be able to evaluate the validity of the PROMIS items in this patient population under acute and stable conditions and evaluate responsiveness of several PROMIS item banks under conditions of known change in an underlying chronic disease. We will also evaluate stability of sub-domains that are not hypothesized to change with COPD exacerbations.
MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
Methods and systems for detecting cancer and/or determining tissue of origin of cancer are disclosed. In some embodiments, a multi-class cancer classifier is disclosed that is trained with a plurality of biological samples comprising cfDNA fragments. The analysis system obtains a feature vector for each sample, and a multiclass classifier predicts a probability likelihood for each originating tissue in a plurality of originating Tissue (TOO) classes. In some embodiments, the plurality of TOO categories includes a subset of blood, including both hematologic malignancies and precursor disorders. In one embodiment, non-cancer samples with high tissue signal are pruned from the training sample set. In another embodiment, the analysis system stratifies the samples according to tissue signals and applies binary truncation thresholds determined for each layer.
Movement disorders are a group of neurological conditions that alter human movements. They lead to functional impairments, diminished quality of life, and significant societal, economic, and familial burden. Due to the increase in population and longer life expectancy \[1\], more and more people will have to live with movement disorders. However, access to movement disorder specialists is already limited and will get worse \[2\]. Therefore, there is an urgent need to develop tools to aid non-specialist medical professionals identify and manage the symptoms (both motor and non-motor) of those disorders such that specialist can focus on more severe and complex cases. While there are several conditions that can be classified as movement disorders, the current proposal will focus on six disorders that have overlapping symptoms and could prove difficult to differentiate for non-specialists and/or clinicians that do not readily have access to genetic testing or imaging facilities: Essential tremor (ET), Parkinson's disease (PD), Huntington's disease (HD), primary focal dystonia (PFD), spinocerebellar ataxia (SCA), and functional movement disorders (FMD). While trained movement disorder specialists may correctly identify each of these disorders and provide optimal treatment, general practitioners and clinicians living in rural areas that do not have access to the most up-to-date diagnostic tools, such as neuroimaging and genetic testing, may face difficulty when treating those patients due to symptom variability and overlap in symptom presentation between different disorders; leading to sub-optimal treatment outcomes. As such, the development of simple, accurate, and inexpensive tools to help guide their clinical decisions is warranted. The ubiquity of mobile technology and wearable sensors may enable the development of such a tool. In recent years, our group and others have used mobile phones and wearable technology to assess symptoms in a multitude of disorders. This highlights the feasibility of our proposed system for the assessment and monitoring of symptom severity in individuals with movement disorders.
Bruxism is a parafunctional or unconscious act of grinding or clenching the teeth. The factors contributing to bruxism are thought to include joint and soft tissue injuries, genetic factors, fatigue, and stress. There is a consensus that the etiology of bruxism is multifactorial and originates from central mechanisms. Bruxism is a common parafunctional activity in the general population, occurring both during sleep and while awake. Daytime bruxism, which is more prevalent in women, affects approximately 20% of the adult population, while sleep bruxism affects around 10%. Overall, the prevalence of bruxism decreases with age, regardless of gender.

The treatment of bruxism aims to raise awareness of oral parafunctional behaviors, alleviate pain, establish a resting position for the temporomandibular joint, improve posture in the head and neck regions, restore muscle strength between affected muscles, and achieve pain-free range of motion. While there is no definitive treatment method, a variety of invasive (acupuncture, injections, surgery, etc.) and non-invasive (exercise, electrical stimulation, manual trigger point stimulation, taping, etc.) approaches are employed. In recent years, reversible non-invasive approaches have gained importance in treatment.

Taping and bandaging have long been part of physiotherapy practices as treatment methods. Kinesio® Tape is a latex-free, thin, cotton-based tape. Developed in Japan 25 years ago, Kinesio® Tape has become widely used in recent years, not only in the United States, Europe, and many other parts of the world but also in our country. The structure, thickness, and weight of the tape are similar to the physical properties of the skin, with a high degree of longitudinal elasticity. The tension levels of the tapes vary depending on the treatment purpose. The primary goal of the Kinesio taping method is to support healing by allowing pain-free movement. In the Kinesio taping method, the tape is applied around or over the muscles as needed to prevent muscle overactivity.

Psychological counseling and exercise are widely used techniques in the treatment of temporomandibular dysfunction (TMD) and have been shown to have positive outcomes in the literature. In a randomized controlled trial by Nimela et al., the efficacy of counseling and masticatory muscle exercises alone was found to be similar to that of stabilization splints in both pain relief and increasing active maximal mouth opening. In a study by Coşkun et al., the addition of kinesio taping to counseling and exercises resulted in significantly greater benefits in both the short and long term. While the beneficial effects of exercise and kinesio taping on TMD and bruxism have been confirmed in various studies, research investigating their impact on cervical awareness is quite limited. Therefore, the aim of this study is to examine the effects of kinesio taping, in addition to exercise, on pain, temporomandibular joint range of motion, sleep quality, depression levels, and cervical awareness in individuals with bruxism.
This invention relates to a novel method of reducing the appearance of rhytides (“facial wrinkles”) and/or infra-orbital shadows (“dark circles”) under the eyes, and striae (“stretch marks”), or lentigo senilis (“age spots”), and hyper/hypo pigmentation on other anatomical areas. Particularly, this invention relates to a topical patch worn on the skin that in a preferred embodiment incorporates two distinct layers, each providing useful features and together providing a novel article and method of improving skin cosmesis. Ease of use, patient comfort and cost effectiveness are provided. The patch is applied to the affected area and preferably worn at least several hours and more preferably worn overnight. The product increases the hydration level of the skin over which it is applied. There is a slight increase to the volume of the local superficial tissue, which serves to tighten the overlying skin and reduce the size and quantity of fine wrinkles at least temporarily. Various active ingredients, such as peptides, vitamin compounds, antioxidants, growth factors, glycolic or alphahydroxy acids, etc., may be incorporated into the present invention thereby providing an enhanced effect or other perceived advantage in the market. 
     20
This is a within-participant study with two arms. All participants receive the Virtual Training with one target task and they are tested (after one day and one month) on the target task (arm 1) and as well as on a control task(arm 2). Assignment to the specific task that is trained is randomized across participants.
Copper is primarily excreted in the bile. Excretion is decreased in patients with cholestasis and/or cirrhosis. Manganese is found, and presumed to be excreted, in bile [see Clinical Pharmacology (12.3)]. Hepatic accumulation of copper and manganese have been reported with long-term administration in parenteral nutrition at dosages higher than recommended [see Warnings and Precautions (5.4)].

For patients with cholestasis, biliary dysfunction, or cirrhosis, monitor hepatic and biliary function during long-term administration of Tralement. If a patient develops signs or symptoms of hepatic or biliary dysfunction during use of Tralement, obtain serum concentrations of copper and ceruloplasmin as well as manganese whole blood concentrations. Consider using individual trace element products in patients with hepatic and/or biliary dysfunction.
OBJECTIVES: Music is helpful to young people in healthcare contexts, but less is known about the acceptability of music-based interventions for youth living at home with chronic pain who may be struggling to attend school and participate in social activities. The Songs of Love (SOL) foundation is a national nonprofit organization that creates free, personalized, original songs for youth facing health challenges. The aims of this study were (1) to assess acceptability of SOL from the perspective of youth with chronic pain receiving a song and singer-songwriters who created the songs, and (2) to explore the role of music more generally in the lives of young people living with pain.
METHODS: Twenty-three people participated. Fifteen youth (mean age 16.8) were interviewed and received a song, and six singer-songwriters were interviewed about creating the songs. (Two additional people participated in pilot interviews.) Acceptability was assessed by (1) proportion of youth who participated in a second interview about their song and (2) results of reflexive thematic analysis (RTA) to determine acceptability. Themes addressing the role of music in the lives of youth with pain were also explored using RTA.
RESULTS: The program was acceptable as 12 of 15 youth (80 %) participated in second interviews and themes met the definition of acceptability. Three themes addressing the role of music in the lives of youth living with pain were identified.
CONCLUSIONS: This is the first report of the acceptability and experience of SOL and contributes to research on the benefits of music for pain management.
BACKGROUND: Neonatal hypoxic-ischemic brain injury (HIBI) results from disruptions to blood supply and oxygen in the perinatal brain. The goal of this study was to measure brain sterol metabolites and plasma oxysterols after injury in a neonatal HIBI mouse model to assess for potential therapeutic targets in the brain biochemistry as well as potential circulating diagnostic biomarkers.
METHODS: Postnatal day 9 CD1-IGS mouse pups were randomized to HIBI induced by carotid artery ligation followed by 30 minutes at 8% oxygen or to sham surgery and normoxia. Brain tissue was collected for sterol analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Plasma was collected for oxysterol analysis by LC-MS/MS.
RESULTS: There were minimal changes in brain sterol concentrations in the first 72 hours after HIBI. In severely injured brains, there was a significant increase in desmosterol, 7-DHC, 8-DHC, and cholesterol 24 hours after injury in the ipsilateral tissue. Lanosterol, 24-dehydrolathosterol, and 14-dehydrozymostenol decreased in plasma 24 hours after injury. Severe neonatal HIBI was associated with increased cholesterol and sterol precursors in the cortex at 24 hours after injury.
CONCLUSIONS: Differences in plasma oxysterols were seen at 24 hours but were not present at 30 minutes after injury, suggesting that these sterol intermediates would be of little value as early diagnostic biomarkers.
INTRODUCTION: Peritoneal dialysis (PD) is an effective treatment  modality for advanced kidney failure, offering patients a significant  degree of independence. However, the long-term use of PD is  limited due to the degeneration of the peritoneal membrane,  resulting in reduced dialysis adequacy. Evaluating the peritoneal  membrane condition in patients with advanced kidney failure  who are undergoing PD is challenging with existing methods.  Therefore, this study aimed to investigate the correlation between  8-hydroxy-2'-deoxyguanosine (8OHDG) levels in the peritoneal  solution of patients undergoing PD and various factors, such  as peritoneal equilibration test (PET), dialysis adequacy (Kt/V),  underlying diseases, serum ferritin, and albumin levels. 8OHDG  is a sensitive marker of oxidative stress caused by DNA damage.
METHODS: A total of 56 patients were included in this cross-sectional  study. Five milliliters of PD fluid were collected from the patients,  and 8-OHdG levels were measured using ELISA method. Then, they  were compared with PET, Kt/V, albumin, and ferritin markers in  the patients' files, and the results were analyzed by statistical tests.
RESULTS: The study examined the correlation between 8OHDG  and other markers. It was found that this index had significant  associations with PET and underlying HTN (P < .05), whereas no  significant associations were identified with the other markers.
CONCLUSION: The results of the present study demonstrate that  the level of 8OHDG, as one of the oxidative stress markers, could  be used to evaluate the function of the peritoneum in patients  undergoing PD. DOI: 10.52547/ijkd.7654.